Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Selective Potassium Channel Blocker for Atrial Fibrillation
Pierre Fabre Pharmaceuticals (Pierre Fabre) and Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement for Pierre Fabre’s selective potassium channel blocker, F17727.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180104005695/en/
F17727 is a small molecule in late preclinical development for the potential treatment of atrial fibrillation (AF). Under the terms of the agreement, Pierre Fabre grants Boston Pharmaceuticals worldwide exclusive rights for the development, manufacturing and commercialization of F17727. Financial terms of the agreement were not disclosed.
“While our R&D and commercial focus has shifted away from cardiology, we are committed to ensuring that promising compounds are advanced through strategic partnerships to the benefit of patients,” said Frédéric Duchesne, President & CEO, Pierre Fabre Pharmaceuticals. “Boston Pharmaceuticals’ R&D excellence, collaborative approach and dedication to patients aligns well with our mission and we are pleased to enter this agreement with them for F17727.”
“This agreement, with such a patient-driven and innovative partner as Pierre Fabre, marks a further significant step in our plan to assemble a diverse portfolio of clinical candidates across a broad range of mechanisms and therapeutic targets. F17727 represents the seventh addition to our rapidly advancing pipeline and our first candidate that addresses cardiovascular disease,” said Robert Armstrong, Chief Executive Officer of Boston Pharmaceuticals. “We believe F17727 works through a potentially differentiated, highly selective mechanism with the potential to treat atrial fibrillation and look forward to advancing this candidate to further evaluate its potential.”
For more information, please visit www.pierre-fabre.com
For more information, please visit www.bostonpharmaceuticals.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Westinghouse AP1000® Plant to Load Fuel25.4.2018 15:14 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) and CNNC Sanmen Nuclear Power Company Limited (SMNPC) announced today that the world’s first unit of AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China, has received the fuel load permit from China’s National Nuclear Safety Administration (NNSA) and has commenced initial fuel loading. “Today we have reached a tremendous milestone for Westinghouse and our AP1000 plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “This is the next major step in delivering the world’s first AP1000 plant to our customer and demonstrating the benefits of our advanced passive safety technology to the world.” Sanmen Unit 1 has successfully completed all the necessary functional tests as well as technical, safety and Chinese regulatory reviews. The fuel load process will be followed by initial criticality, initial synchronization to the electrical grid, a
Elliott Advisors (UK) Limited Statement on Whitbread25.4.2018 15:03 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”) is pleased that Whitbread has announced a demerger and has committed to doing so “as fast as practical”. In Elliott’s view this should be achieved within six months. About Elliott Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005814/en/ Contact information Media Contacts Elliott Advisors (UK) Limited Sarah Rajani CFA Director of Communications Elliott Advisors (UK) Limited +44 (0) 20 3009 1818 srajani@elliott
Incognito Launches Digital Home Experience Solution25.4.2018 15:00 | Tiedote
Incognito Software Systems, a global provider of device and service management solutions for digital service providers, today introduced the Digital Home Experience Solution. The new offering enhances the existing Incognito Auto Configuration Server with improved digital channels, and analytics to address service quality challenges associated with complex, multi-device home WiFi networks. In production with a Tier 1 service provider, the solution is accelerating technical problem resolution, reducing operational costs with fewer truck rolls, while improving customer satisfaction. “Digital transformation in the home network is accelerating, as service providers look to eliminate friction points such as how to automate the resolution of service quality issues,” said Anil Rao, Principal Analyst, Analysys Mason. “It is in this context that Incognito’s new Digital Home Experience Solution is relevant. Communication service providers are investing in such solutions to boost customer satisfac
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries25.4.2018 14:30 | Tiedote
Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy. Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration. “The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-c
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work25.4.2018 14:00 | Tiedote
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas. Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round. “We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company,” said Marc de Garidel, Chief Executive Officer of Corvidia Therapeutics Inc. “This funding is critical
LTI Congratulates American Modern Insurance Group, Inc. for Winning the Celent 2018 Model Insurer Award25.4.2018 13:30 | Tiedote
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, congratulates its client, American Modern Insurance Group, Inc. (American Modern) for winning Celent’s 2018 Model Insurer award. Celent is a global research and advisory firm for the financial services industry. American Modern, located in suburban Cincinnati, Ohio, provides specialty insurance products and services for the residential property and recreational markets. Celent’s annual Model Insurer Awards recognize the best practices of technology usage in areas critical to success in the insurance industry. American Modern is honored with a Celent 2018 Model Insurer award for operational excellence for its automation efforts that resulted in increased productivity and improved customer experience. A detailed case study of each winning initiative, including American Modern, is included in Celent’s annual Model Insurer report. Anil Vazirani, Chief Business Officer, Insur
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme